Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Cancer Discov. 2017 Oct 3;7(11):1336–1353. doi: 10.1158/2159-8290.CD-17-0267

Figure 4. TOX is required for continued human T-ALL growth and maintenance.

Figure 4

(a) Western blot analysis following stable shRNA knockdown in human T-ALL cells. Percent knockdown noted. (b) Cell viability following knockdown as assessed by Cell TiterGlo. (c) EdU proliferation analysis. (d) Annexin-V staining. Asterisks in b-d denote p<0.05, Student’s t-test. Xenograft studies performed with human HPB-ALL (e-g) and CCRF-CEM (h-j). (e,h) Flow cytometry analysis showing efficiency of TOX knockdown. (f,i) Luciferase bioluminescent imaging of representative animals engrafted at 0 days compared with 21 days. Scramble shRNA control (left flank) or shRNA-TOX #2 (right flank). (g,j) Quantification of xenograft growth using two independent shRNAs. Not significant (NS), p<0.05 (*), p<0.01 (**), and p<0.001 (***), ANOVA test.